Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Nat Commun ; 9(1): 3198, 2018 08 10.
Article in English | MEDLINE | ID: mdl-30097569

ABSTRACT

EGFR tyrosine kinase inhibitors cause dramatic responses in EGFR-mutant lung cancer, but resistance universally develops. The involvement of ß-catenin in EGFR TKI resistance has been previously reported, however, the precise mechanism by which ß-catenin activation contributes to EGFR TKI resistance is not clear. Here, we show that EGFR inhibition results in the activation of ß-catenin signaling in a Notch3-dependent manner, which facilitates the survival of a subset of cells that we call "adaptive persisters". We previously reported that EGFR-TKI treatment rapidly activates Notch3, and here we describe the physical association of Notch3 with ß-catenin, leading to increased stability and activation of ß-catenin. We demonstrate that the combination of EGFR-TKI and a ß-catenin inhibitor inhibits the development of these adaptive persisters, decreases tumor burden, improves recurrence free survival, and overall survival in xenograft models. These results supports combined EGFR-TKI and ß-catenin inhibition in patients with EGFR mutant lung cancer.


Subject(s)
Carcinoma, Non-Small-Cell Lung/genetics , Lung Neoplasms/genetics , Mutation/genetics , Protein Kinase Inhibitors/pharmacology , Receptor, Notch3/metabolism , Signal Transduction , beta Catenin/metabolism , Animals , Carcinoma, Non-Small-Cell Lung/blood , Carcinoma, Non-Small-Cell Lung/pathology , Cell Line, Tumor , DNA-Binding Proteins/metabolism , Drug Resistance, Neoplasm/drug effects , Epithelial-Mesenchymal Transition/drug effects , ErbB Receptors/genetics , Humans , Lung Neoplasms/blood , Lung Neoplasms/pathology , Mice, Inbred NOD , Mice, SCID , Neoplastic Stem Cells/drug effects , Neoplastic Stem Cells/metabolism , Neoplastic Stem Cells/pathology , Phenotype , Plasminogen Activator Inhibitor 1/blood , Protein Stability/drug effects , Transcription Factors/metabolism , beta Catenin/antagonists & inhibitors
3.
Am J Hum Genet ; 95(2): 218-26, 2014 Aug 07.
Article in English | MEDLINE | ID: mdl-25087613

ABSTRACT

Centronuclear myopathies (CNMs) are characterized by muscle weakness and increased numbers of central nuclei within myofibers. X-linked myotubular myopathy, the most common severe form of CNM, is caused by mutations in MTM1, encoding myotubularin (MTM1), a lipid phosphatase. To increase our understanding of MTM1 function, we conducted a yeast two-hybrid screen to identify MTM1-interacting proteins. Striated muscle preferentially expressed protein kinase (SPEG), the product of SPEG complex locus (SPEG), was identified as an MTM1-interacting protein, confirmed by immunoprecipitation and immunofluorescence studies. SPEG knockout has been previously associated with severe dilated cardiomyopathy in a mouse model. Using whole-exome sequencing, we identified three unrelated CNM-affected probands, including two with documented dilated cardiomyopathy, carrying homozygous or compound-heterozygous SPEG mutations. SPEG was markedly reduced or absent in two individuals whose muscle was available for immunofluorescence and immunoblot studies. Examination of muscle samples from Speg-knockout mice revealed an increased frequency of central nuclei, as seen in human subjects. SPEG localizes in a double line, flanking desmin over the Z lines, and is apparently in alignment with the terminal cisternae of the sarcoplasmic reticulum. Examination of human and murine MTM1-deficient muscles revealed similar abnormalities in staining patterns for both desmin and SPEG. Our results suggest that mutations in SPEG, encoding SPEG, cause a CNM phenotype as a result of its interaction with MTM1. SPEG is present in cardiac muscle, where it plays a critical role; therefore, individuals with SPEG mutations additionally present with dilated cardiomyopathy.


Subject(s)
Cardiomyopathy, Dilated/genetics , Muscle Proteins/genetics , Myopathies, Structural, Congenital/genetics , Protein Serine-Threonine Kinases/genetics , Protein Tyrosine Phosphatases, Non-Receptor/genetics , Amino Acid Sequence , Animals , Child , Child, Preschool , Disease Models, Animal , Female , Humans , Infant, Newborn , Male , Mice , Mice, Knockout , Muscle Proteins/metabolism , Mutation , Myocardium/cytology , Myofibrils/genetics , Phosphatidylinositol Phosphates/biosynthesis , Protein Serine-Threonine Kinases/metabolism , Protein Tyrosine Phosphatases, Non-Receptor/metabolism , Sarcoplasmic Reticulum/genetics , Sarcoplasmic Reticulum/pathology , Sequence Alignment , Sequence Analysis, DNA , Turkey , Two-Hybrid System Techniques
4.
Proteomics ; 13(20): 3013-29, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23983189

ABSTRACT

Multiple myeloma (MM) is a hematological malignancy caused by a microenviromentally aided persistence of plasma cells in the bone marrow. The role that extracellular vesicles (EVs), microvesicles and exosomes, released by MM cells have in cell-to-cell communication and signaling in the bone marrow is currently unknown. This paper describes the proteomic content of EVs derived from MM.1S and U266 MM cell lines. First, we compared the protein identifications between the vesicles and cellular lysates of each cell line finding a large overlap in protein identifications. Next, we applied label-free spectral count quantitation to determine proteins with differential abundance between the groups. Finally, we used bioinformatics to categorize proteins with significantly different abundances into functional groups. The results illustrate the first use of label-free spectral counting applied to determine relative protein abundances in EVs.


Subject(s)
Cytoplasmic Vesicles/metabolism , Multiple Myeloma/metabolism , Staining and Labeling/methods , Cell Extracts , Cell Line, Tumor , Chromatography, Liquid , Cytoplasmic Vesicles/ultrastructure , Humans , Mass Spectrometry , Multiple Myeloma/ultrastructure , Neoplasm Proteins/metabolism , Proteomics , Reproducibility of Results
5.
J Exp Med ; 210(5): 951-68, 2013 May 06.
Article in English | MEDLINE | ID: mdl-23610125

ABSTRACT

Numerous studies have described the altered expression and the causal role of microRNAs (miRNAs) in human cancer. However, to date, efforts to modulate miRNA levels for therapeutic purposes have been challenging to implement. Here we find that nucleolin (NCL), a major nucleolar protein, posttranscriptionally regulates the expression of a specific subset of miRNAs, including miR-21, miR-221, miR-222, and miR-103, that are causally involved in breast cancer initiation, progression, and drug resistance. We also show that NCL is commonly overexpressed in human breast tumors and that its expression correlates with that of NCL-dependent miRNAs. Finally, inhibition of NCL using guanosine-rich aptamers reduces the levels of NCL-dependent miRNAs and their target genes, thus reducing breast cancer cell aggressiveness both in vitro and in vivo. These findings illuminate a path to novel therapeutic approaches based on NCL-targeting aptamers for the modulation of miRNA expression in the treatment of breast cancer.


Subject(s)
Breast Neoplasms/genetics , Breast Neoplasms/pathology , Gene Expression Regulation, Neoplastic , MicroRNAs/genetics , Phosphoproteins/metabolism , RNA-Binding Proteins/metabolism , Animals , Aptamers, Nucleotide/pharmacology , Cell Line, Tumor , Cell Proliferation , Estradiol/analogs & derivatives , Estradiol/pharmacology , Female , Fulvestrant , Gene Knockdown Techniques , Gene Silencing , Genes, Neoplasm/genetics , Guanine , HEK293 Cells , Humans , Mice , Mice, Nude , MicroRNAs/metabolism , Neoplasm Invasiveness , Neoplasm Metastasis , Oligodeoxyribonucleotides/pharmacology , Transcription, Genetic , Up-Regulation , Nucleolin
6.
Hum Mol Genet ; 19(2): 364-73, 2010 Jan 15.
Article in English | MEDLINE | ID: mdl-19880419

ABSTRACT

Mutations in the gene encoding the cholesterol biosynthetic enzyme NSDHL are associated with the X-linked male-lethal bare patches (Bpa) mouse. Mutant male embryos for several Nsdhl alleles die in midgestation with placental insufficiency. We examined here a possible role of the maternal genotype in such placental pathology. Pre-pregnancy plasma cholesterol levels were similar between wild-type (WT) and Bpa(1H)/+ dams fed a standard, cholesterol-free diet. However, there was a marked decrease in cholesterol levels between embryonic day (E)8.5 and E10.5 for both genotypes. Further, there was a significant lag between E11.5 and E13.5 (P = 0.0011) in the recovery of levels in Bpa(1H)/+ dams to their pre-pregnancy values. To investigate possible effects of the maternal genotype on fetal placentation, we generated transgenic mice that expressed human NSDHL and rescued the male lethality of the Bpa(1H) null allele. We then compared placenta area at E10.5 in WT and Bpa(1H)/+ female embryos where the mutant X chromosome was transmitted from a heterozygous mother or a rescued mutant father. In mutant conceptuses, placental areas were approximately 50% less than WT. Surprisingly, expression of Nsdhl in trophoblast lineages of the placenta and yolk sac endoderm, which occurs only from the maternally inherited allele in a female embryo, had the largest effect on placental area (-0.681 mm(2); P < 0.0001). The maternal genotype had a smaller effect, independent of the fetal genotype (-0.283 mm(2); P = 0.024). These data demonstrate significant effects of the mother and fetal membranes on pregnancy outcome, with possible implications for cholesterol homeostasis during human pregnancy.


Subject(s)
3-Hydroxysteroid Dehydrogenases/genetics , 3-Hydroxysteroid Dehydrogenases/metabolism , Extraembryonic Membranes/metabolism , Genetic Diseases, X-Linked/embryology , Genetic Diseases, X-Linked/genetics , Placenta/pathology , 3-Hydroxysteroid Dehydrogenases/deficiency , Animals , Cholesterol/metabolism , Disease Models, Animal , Embryo, Mammalian , Extraembryonic Membranes/embryology , Extraembryonic Membranes/pathology , Female , Genetic Diseases, X-Linked/metabolism , Genetic Diseases, X-Linked/pathology , Genotype , Heterozygote , Humans , Male , Maternal-Fetal Exchange , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Placenta/embryology , Placenta/metabolism , Pregnancy
7.
Am J Phys Anthropol ; 140(2): 216-33, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19350641

ABSTRACT

Previous research has demonstrated that great ape and macaque males achieve large canine crown sizes primarily through extended canine growth periods. Recent work has suggested, however, that platyrrhine males may achieve larger canine sizes by accelerating rather than prolonging growth. This study tested the hypothesis that the ontogenetic pathway leading to canine sexual dimorphism in catarrhines differs from that of platyrrhines. To test this hypothesis, males and females of several catarrhine genera (Hylobates, Papio, Macaca, Cercopithecus, and Cercocebus) and three platyrrhine genera (Cebus, Ateles, and Callicebus) were compared in the number and spacing of perikymata (enamel growth increments) on their canine crowns. In addition, perikymata periodicities (the number of days of growth perikymata represent) were determined for five genera (Hylobates, Papio, Macaca, Cebus, and Ateles) using previously published as well as original data gathered for this study. The central findings are as follows: 1) males have more perikymata than females for seven of eight genera (in five of the seven, the differences are statistically significant); 2) in general, the greater the degree of sexual dimorphism, the greater the sex difference in male and female perikymata numbers; 3) there is no evidence of a systematic sex difference in primate periodicities; and 4) there is some evidence that sex differences in enamel formation rates may make a minor contribution to canine sexual dimorphism in Papio and Cercopithecus. These findings strongly suggest that in both catarrhines and platyrrhines prolongation of male canine growth is the primary mechanism by which canine crown sexual dimorphism is achieved.


Subject(s)
Catarrhini/anatomy & histology , Cuspid/anatomy & histology , Platyrrhini/anatomy & histology , Sex Characteristics , Animals , Dental Enamel/anatomy & histology , Dental Enamel/growth & development , Female , Male , Tooth Crown/anatomy & histology
SELECTION OF CITATIONS
SEARCH DETAIL
...